
025 - The Parenteral Drug Association & Evolution of Drug Development with Michael Carroll
Mar 12, 2021 - 00:31:51
Radio and PodcastLive Radio & Podcasts
What We Covered 00:51 – Meranda and Ed discuss the Regulatory Odd Couple blog series and constructing the CTD Module 3 11:54 – Ed explains the importance of building the Quality Overall Summary (QOS) and the different st...
021 - Regulatory Odd Couple with Ed Narke & Meranda Parascandola is an episode from CMC Live - Chemistry, Manufacturing & Controls by DSI. What We Covered 00:51 – Meranda and Ed discuss the Regulatory Odd Couple blog series and constructing...
This episode belongs to CMC Live - Chemistry, Manufacturing & Controls.
Use the player on this page to stream the episode online.
Published Feb 12, 2021, 01:00:18 long, audio available.
What We Covered 00:51 – Meranda and Ed discuss the Regulatory Odd Couple blog series and constructing the CTD Module 3 11:54 – Ed explains the importance of building the Quality Overall Summary (QOS) and the different starting points for drug process development 19:45 – Ed and Meranda talk about characterization, the process of manufacturing drug substances/products and the importance of excipients 37:44 – Ed expounds on the analytical aspect of API and regulatory drug development 46:55 – Ed and Meranda share their thoughts on the process of packaging drug substances 49:09 – Ed and Meranda discuss the role that stability plays in development methods 53:42 – P2 Pharmaceutical Development Tweetable Quotes “If anyone’s listening and not familiar with the drug development process, the one area that’s most important is the FDA guidance.” “Characterization is, in my mind, one of the fundamentals of a product and a process and a program. If you don’t know what you’re dealing with to start, it’s hard to catalog it, make it consistently and answer questions about it.” “This is probably, in some folks’ minds, the most important. It’s the manufacturing of the drug substance and the drug product. If you don’t have a process, you don’t have a product.” “There are a few caveats to excipients. One of the things you’ll want to recognize and a question that might come up is ‘are they of human or animal origin?’ And the other big thing is ‘are they novel?’” “Any changes to anything in the program – process-wise or control-wise – late in the game could be a problem because you’re gonna have to generate additional data. There’s an unknown there. What does that change mean?” Relevant Links Design Space InPharmatics – LinkedIn Design Space InPharmatics – Twitter Edward Narke on LinkedIn Odd Couple Series
You can listen to 021 - Regulatory Odd Couple with Ed Narke & Meranda Parascandola online on Radio and Podcast. Open the player on this page to stream the available audio.
021 - Regulatory Odd Couple with Ed Narke & Meranda Parascandola is an episode from CMC Live - Chemistry, Manufacturing & Controls by DSI.
This episode is 01:00:18 long.
This episode was published on Feb 12, 2021.
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Yes. This page shows related episodes from CMC Live - Chemistry, Manufacturing & Controls when more episodes are available from the podcast feed.
You can listen to 021 - Regulatory Odd Couple with Ed Narke & Meranda Parascandola on this page when the episode audio is available from the podcast feed.
021 - Regulatory Odd Couple with Ed Narke & Meranda Parascandola is from CMC Live - Chemistry, Manufacturing & Controls by DSI.
Published Feb 12, 2021 and 01:00:18 long